FDAapproval85% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (her2) as Merck Sharp & Dohme LLC; the shared HER2 mechanism makes the regulatory bar more directly transferable.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Breast Cancer
- Sub-indication
- HER2
Related signal: Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer